RxDoctor Payments Data

Shahid Qamar, MD

Advanced Heart Failure and Transplant Cardiology · Orlando, FLNPI 1912184730

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,450 of the $8,893 with a category attached, or 61.3%. AstraZeneca accounts for 64.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2020 at $3,486 and has fallen 86.9% since, to $456 in 2025.

$8,893in general payments, 2019–2025

Across 119 payments — averaging $74.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Abbott$835
  • Actelion Pharmaceuticals US, Inc.$424
  • United Therapeutics Corporation$297
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$297
  • Impulse Dynamics (USA) Inc.$286
  • plus $1K from 15 others
$28,929in research payments, 2019–2025

Across 9 payments — averaging $3214.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$14K
  • Alnylam Pharmaceuticals Inc.$11K
  • Analog Devices Inc.$4K

What the payments were for

  • Speaking & faculty fees$5,45061%
  • Food & beverage$3,25337%
  • Education$1912%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,893 in reported general payments places this provider in the 60th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

See all advanced heart failure and transplant cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$253,892
Medicare patients
922
Services billed
2,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis293$6,698,954
EntrestoSacubitril/Valsartan278$314,950
EliquisApixaban252$284,798
JardianceEmpagliflozin233$264,243
FarxigaDapagliflozin Propanediol103$106,281
XareltoRivaroxaban31$38,779
Milrinone Lactate23$6,927
Torsemide180$4,749
Metoprolol Succinate243$3,380
Midodrine Hcl39$2,722
Bumetanide73$2,668
Ranolazine ErRanolazine20$2,086
Enoxaparin Sodium16$1,729
Atorvastatin Calcium189$1,610
Spironolactone232$1,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$79$6,983,752545 claims
NovartisEntresto$163$314,950278 claims
Boehringer IngelheimJardiance$35$264,243233 claims
AstraZenecaFarxiga$5,753$106,281103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

Other advanced heart failure and transplant cardiology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →